Leaflet LIPOCOMB 10mg / 10mg capsules

Indicated for: dyslipidemia

Substance: rosuvastatin + ezetimibe (statin lipid-lowering agent + lipid-lowering agent)

ATC: C10BA06 (Cardiovascular system | Lipid modifying agents, combinations | Combinations of various lipid modifying agents)

The combination of rosuvastatin and ezetimibe is used to treat hypercholesterolemia (high cholesterol levels) and to prevent cardiovascular diseases in high-risk patients. It combines two complementary mechanisms to lower LDL cholesterol ('bad cholesterol') levels and improve the lipid profile.

- Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol synthesis in the liver, lowering LDL cholesterol and triglycerides while increasing HDL cholesterol ('good cholesterol').
- Ezetimibe works by inhibiting the absorption of cholesterol in the intestines, reducing the amount of cholesterol that enters the bloodstream.

This combination is indicated for patients who cannot achieve target cholesterol levels with statins alone or who require more intensive LDL cholesterol reduction. The medication is taken orally, usually once daily, and the dose is adjusted based on the patient’s needs.

Common side effects include muscle pain, headache, nausea, fatigue, and abdominal discomfort. In rare cases, more serious reactions such as liver dysfunction or rhabdomyolysis (a condition involving muscle tissue breakdown) may occur. Regular monitoring of liver function and lipid levels is essential during treatment.

Treatment with rosuvastatin and ezetimibe should be administered under the supervision of a doctor, and patients should follow a low-fat, low-cholesterol diet to maximize the benefits of therapy.